肺动脉高压药物治疗中血氧饱和度下降患者结局
该回顾性研究基于法国肺动脉高压注册库,分析719例PAH患者,发现173例(24%)在PAH药物治疗期间出现动脉血氧饱和度下降≥3%。这些患者诊断时年龄更大、一氧化碳弥散量更低、6分钟步行距离更短,再评估时达到ESC/ERS低风险标准的比例更低、长期氧疗启动更多(16% vs 5%,p<0.001),且生存更差(HR 1.81,95%CI 1.43-2.34;p<0.0001)。
要点
- PAH药物治疗中约24%患者出现SaO2下降≥3%。
- SaO2下降≥3%与更差生存独立相关(HR 1.81)。
- 此类患者再评估达低风险标准比例更低、氧疗启动更多。
核心结论
- 接受PAH药物治疗的患者中,较大比例出现SaO2下降≥3%,且与更差长期结局和生存降低相关。
研究设计与样本
- 法国肺动脉高压注册库的回顾性研究,共审查719例PAH患者。
- 排除与先天性心脏病相关的PAH及具有明显静脉/毛细血管受累特征的PAH。
主要发现
- 173例(24%)患者出现SaO2下降≥3%。
- 与未出现SaO2下降≥3%者相比,这些患者诊断时年龄更大、DLCO更低、6分钟步行距离更短。
- 再评估时达到ESC/ERS低风险标准的比例显著更低,启动长期氧疗者更多(16% vs 5%;p<0.001)。
- SaO2下降≥3%与更差生存相关(HR 1.81,95%CI 1.43-2.34;p<0.0001)。
- 多变量Cox分析中,SaO2下降≥3%是独立于诊断时年龄和随访时ESC/ERS风险分层的预后因素。
关键数值与推荐
- SaO2下降≥3%为暴露定义。
- 长期氧疗启动比例:SaO2下降≥3%组16% vs 未下降组5%(p<0.001)。
- 生存风险比:HR 1.81(95%CI 1.43-2.34;p<0.0001)。
临床怎么用
- PAH药物治疗期间应监测SaO2变化,下降≥3%提示预后较差。
- 对出现SaO2下降≥3%的患者,可考虑更密切随访并评估长期氧疗指征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drugs approved for the treatment of pulmonary arterial hypertension (PAH) improve long-term outcomes. These drugs have pulmonary vasodilator properties which may potentially cause a decrease in arterial oxyhaemoglobin saturation (S aO2 ) in some patients. The present retrospective study of the French Pulmonary Hypertension Registry aimed to describe the clinical characteristics and outcomes of patients showing a ≥3% decrease in S aO2 while treated with PAH drugs. METHODS: We reviewed 719 PAH patients. The exclusion criteria were PAH associated with congenital heart disease and PAH with overt features of venous/capillaries involvement. RESULTS: 173 (24%) patients had a ≥3% decrease in S aO2 . At diagnosis, they were older with a lower diffusing capacity of the lung for carbon monoxide and a shorter 6-min walk distance compared with those who did not display a ≥3% decrease in S aO2 . The percentage of patients meeting the European Society of Cardiology/European Respiratory Society (ESC/ERS) low-risk criteria at re-evaluation was significantly lower in those with a ≥3% decrease in S aO2 and more patients started long-term oxygen therapy in this group (16% versus 5%; p<0.001). A ≥3% decrease in S aO2 was associated with a poorer survival (hazard ratio 1.81, 95% CI 1.43-2.34; p<0.0001). In a multivariate Cox analysis, a ≥3% decrease in S aO2 was a prognostic factor independent of age at diagnosis and ESC/ERS risk stratification at follow-up. CONCLUSIONS: When treated with PAH drugs, a large subset of patients experience a ≥3% decrease in S aO2 , which is associated with worse long-term outcomes and reduced survival.
引用
- Valentin S, Maurac A, Sitbon O, et al. Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. Eur Respir J. 2021. PMID: 33875491. doi:10.1183/13993003.04066-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。